Skip to content
Screener

Avalo Therapeutics AVTX Price / earnings

Price / earnings at other companies

Eli Lilly logo
Eli LillyLLY
40×-10.6×
AbbVie logo
AbbVieABBV
70.5×-16.6×

Other financials

Income statement

See full
Revenue$59.0K-69.3%
Gross profit$963.0K+8,855%
Operating income-$31.5M-63.2%
Net income-$36.4M-75.1%
EPS (diluted)-$0.83+56.8%

Balance sheet

See full
Cash & equivalents$85.6M+101%
Total debt$242.0K-64.4%
Total equity$448.7M+329%
Total assets$490.8M+288%

Cash flow

See full
Operating cash flow-$20.0M-75.5%
CapEx-—
Free cash flow-$15.0M-444%

Valuation

See full
Market cap$1B+908%
Enterprise value$917.51M+1,512%

Profitability

See full
Gross margin182%+176pp
Operating margin-15,536.1%-17,275pp
Net margin-7,965.8%-10,750pp
FCF margin-11,123.8%-13,374pp

Returns & leverage

See full
Return on equity-36.3%—
Debt / equity0×0.0×
Current ratio19.3×+6.9×

Where this comes from

Calculated from Avalo Therapeutics’s reported figures.

market cap/net income=1.2×

Based on the most recent quarter.

The source filing: Avalo Therapeutics’s 10-Q, filed May 13, 2026. Open the filing →

Filed
May 13, 2026, 7:02 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001534120-26-000033

FAQ

What is Avalo Therapeutics's price / earnings?
Avalo Therapeutics (AVTX) reported price / earnings of 1.2× in Q1 2025.
What does price / earnings mean?
Market capitalization at the quarter end divided by trailing-twelve-month net income. The price the market pays for each dollar of trailing earnings.

Ask your AI about Avalo Therapeutics's price / earnings.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude